Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-107675
Filing Date
2024-12-11
Accepted
2024-12-11 09:27:50
Documents
3
Period of Report
2024-12-11

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0224408-6k_neurosense.htm 6-K 11607
2 PRESS RELEASE, DATED DECEMBER 11, 2024, ENTITLED "NEUROSENSE RECEIVES POSITIVE F ea022440801ex99-1_neurosense.htm EX-99.1 18761
3 GRAPHIC ex99-1_001.jpg GRAPHIC 8414
  Complete submission text file 0001213900-24-107675.txt   43171
Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562
Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142
NeuroSense Therapeutics Ltd. (Filer) CIK: 0001875091 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-41084 | Film No.: 241540376
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)